Press Releases

Advaxis Announces Initiation of Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer

08/05/2021

Excerpt from the Press Release: MONMOUTH JUNCTION, N.J., July 15, 2021 (GLOBE NEWSWIRE) — Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the initiation of its Phase 1 clinical study evaluating ADXS-504 in patients with biochemically recurrent prostate cancer. The study, being conducted at…

Read More

CohBar Provides Update on the Phase 1a/1b Clinical Trial for CB4211 Under Development for NASH and Obesity

08/04/2021

Excerpt from the Press Release: MENLO PARK, Calif., July 14, 2021 (GLOBE NEWSWIRE) — CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced an update on the timing for the release of the data for its Phase 1a/1b clinical study of…

Read More

Summit Therapeutics Presents Breakthrough Research Data from Phase II Studies, including Evidence Validating Microbiome Preservation, for its Investigational Drug Ridinilazole

07/27/2021

Excerpt from the Press Release: Cambridge, MA, July 12, 2021 (GLOBE NEWSWIRE) — Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) is today displaying three preeminent ePosters at the prestigious 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). Two ePosters bring increased awareness and understanding of the significance of data generated using…

Read More

Fulcrum Therapeutics Announces Initiation of Multi-Center Phase 3 (LOSVID) Trial with Losmapimod for Hospitalized COVID-19 Patients

06/25/2020

Excerpt from the press release: “CAMBRIDGE, Mass., June 24, 2020 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it received early notification from the U.S. Food and Drug Administration (FDA) that the company may proceed with initiating…

Read More

NeuroRx and Relief Therapeutics Announce Fast Track Designation Granted by the FDA to RLF-100 (Aviptadil) for the Treatment of Respiratory Distress in COVID-19

06/24/2020

Excerpt from the press release: “RADNOR, Pa. and GENEVA, June 24, 2020 (GLOBE NEWSWIRE) — NeuroRx, Inc., in partnership with RELIEF THERAPEUTICS Holding AG (SIX:RLF) “Relief” today announced that the U.S. Food and Drug Administration (FDA) awarded Fast Track Designation to NeuroRx for the investigation of RLF-100 (Aviptadil) for the treatment of acute lung injury/acute…

Read More

TrialStat invites clinical operations leaders and researchers to join them at this year’s SCOPE Summit to explore the latest advances in data management technology

02/17/2019

Montreal-based TrialStat Solutions Inc., a trusted provider of eClinical technology solutions, will be exhibiting at this year’s Summit for Clinical Operations Executives (SCOPE) in Orlando, FL from February 18-21. Christopher Kata, Director, Sales and Marketing, will be conducting demonstrations of TrialStat’s flexible, leading-edge technology built for the needs of today’s life sciences companies. Join Christopher…

Read More

Meet With TrialStat at SCDM to Learn More About The Latest Version of TrialStat EDC

09/14/2018

TrialStat Launches Updated TrialStat EDC at SCDM, Introducing New Features to Further Simplify Your Data Management and Study Collaboration Needs – Meet with us at Booth #312 As the volume of per-trial data grows, compliance requirements increase, and Sponsors are more responsible than ever for trial oversight, TrialStat has responded by releasing the next generation…

Read More